TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group Study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, Both Twice Daily, in a Pediatric Population During the Fall Viral Season.
Brief Summary: Study ADA113872 is an exploratory 16-week multi-centre, randomized, double-blind, parallel group study in pediatric subjects, 4 to 11 years of age, with a history of seasonal asthma exacerbation(s). Approximately 40 clinical sites in the United States will randomize 316 subjects. Eligible subjects will be randomly assigned to one of two double-blind treatments using a 1:1 randomization. Subjects will be identified for their eligibility for enrolment starting in April 2010. Eligible subjects will be invited to return for randomization into the study in August 2010. This exploratory study is being conducted to assess whether treatment with ADVAIR™ DISKUS™ 100/50 mcg is more effective at reducing the risk of exacerbation and the asthma impairment associated with viral respiratory tract infections during the fall season when compared to treatment with FLOVENT™ DISKUS™ 100 mcg.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort pMDI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide pMDI | Intervention Type: DRUG; Name: Symbicort pMDI; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide pMDI; Assigned to Arm(s): 2
B: Arm Label: FLOVENT™ DISKUS™ 100 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT™ DISKUS™ 100 mcg BID | Arm Label: ADVAIR™ DISKUS™ 100/50 mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR™ DISKUS™ 100/50 mcg BID | Intervention Type: DRUG; Name: FLOVENT™ DISKUS™ 100 mcg BID; Assigned to Arm(s): FLOVENT™ DISKUS™ 100 mcg | Intervention Type: DRUG; Name: ADVAIR™ DISKUS™ 100/50 mcg BID; Assigned to Arm(s): ADVAIR™ DISKUS™ 100/50 mcg
C: Arm Label: Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Vilanterol, Drug: Placebo Inhalation Powder Diskus | Arm Label: Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol Inhalation Powder, Drug: Placebo Inhalation Powder NDPI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhalation Powder NDPI, Drug: Placebo Inhalation Powder Diskus | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Vilanterol | Intervention Type: DRUG; Name: Salmeterol Inhalation Powder; Assigned to Arm(s): Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder NDPI; Assigned to Arm(s): Placebo, Salmeterol | Intervention Type: DRUG; Name: Placebo Inhalation Powder Diskus; Assigned to Arm(s): Placebo, Vilanterol
D: Intervention Type: DRUG; Name: fluticasone propionate/salmeterol powder; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate powder; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel Group Study of ADVAIR™ DISKUS™ 100/50 and FLOVENT™DISKUS™ 100, Both Twice Daily, in a Pediatric Population During the Fall Viral Season.
Brief Summary: Study ADA113872 is an exploratory 16-week multi-centre, randomized, double-blind, parallel group study in pediatric subjects, 4 to 11 years of age, with a history of seasonal asthma exacerbation(s). Approximately 40 clinical sites in the United States will randomize 316 subjects. Eligible subjects will be randomly assigned to one of two double-blind treatments using a 1:1 randomization. Subjects will be identified for their eligibility for enrolment starting in April 2010. Eligible subjects will be invited to return for randomization into the study in August 2010. This exploratory study is being conducted to assess whether treatment with ADVAIR™ DISKUS™ 100/50 mcg is more effective at reducing the risk of exacerbation and the asthma impairment associated with viral respiratory tract infections during the fall season when compared to treatment with FLOVENT™ DISKUS™ 100 mcg.


Options:
A: Intervention Type: DRUG; Name: Montelukast (drug); Assigned to Arm(s): N/A
B: Arm Label: Reference Strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhaled corticosteroids | Arm Label: Biomarker Strategy; Type: EXPERIMENTAL; Interventions: Drug: Inhaled corticosteroids, Procedure: eNO measurement | Intervention Type: DRUG; Name: Inhaled corticosteroids; Assigned to Arm(s): Biomarker Strategy, Reference Strategy | Intervention Type: PROCEDURE; Name: eNO measurement; Assigned to Arm(s): Biomarker Strategy
C: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Biological: Omalizumab, Biological: Placebo fluticasone | Arm Label: Inhaled Corticosteroid Boost Therapy (ICS); Type: EXPERIMENTAL; Interventions: Drug: Inhaled Corticosteroid Boost Therapy (ICS), Biological: Placebo omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo omalizumab, Biological: Placebo fluticasone | Intervention Type: BIOLOGICAL; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Inhaled Corticosteroid Boost Therapy (ICS); Assigned to Arm(s): Inhaled Corticosteroid Boost Therapy (ICS) | Intervention Type: BIOLOGICAL; Name: Placebo omalizumab; Assigned to Arm(s): Inhaled Corticosteroid Boost Therapy (ICS), Placebo | Intervention Type: BIOLOGICAL; Name: Placebo fluticasone; Assigned to Arm(s): Omalizumab, Placebo
D: Arm Label: FLOVENT™ DISKUS™ 100 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: FLOVENT™ DISKUS™ 100 mcg BID | Arm Label: ADVAIR™ DISKUS™ 100/50 mcg; Type: EXPERIMENTAL; Interventions: Drug: ADVAIR™ DISKUS™ 100/50 mcg BID | Intervention Type: DRUG; Name: FLOVENT™ DISKUS™ 100 mcg BID; Assigned to Arm(s): FLOVENT™ DISKUS™ 100 mcg | Intervention Type: DRUG; Name: ADVAIR™ DISKUS™ 100/50 mcg BID; Assigned to Arm(s): ADVAIR™ DISKUS™ 100/50 mcg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The CHIPS Trial (Control of Hypertension In Pregnancy Study)
Brief Summary: The investigators do not know which approach to treatment of non-severe high blood pressure in pregnancy is better for women and babies.

In the CHIPS Trial, the investigators seek to determine whether 'less tight' control (aiming for a diastolic blood pressure \[dBP\] of 100 mmHg), compared with 'tight' control (aiming for a diastolic blood pressure \[dBP\] of 85 mmHg) can decrease the risks of adverse baby outcomes without increasing the risk of problems for the mother.


Options:
A: Arm Label: 'Less tight' control.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intervention is blood pressure management approach | Arm Label: 'Tight' control.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intervention is blood pressure management approach. | Intervention Type: PROCEDURE; Name: Intervention is blood pressure management approach; Assigned to Arm(s): 'Less tight' control. | Intervention Type: PROCEDURE; Name: Intervention is blood pressure management approach.; Assigned to Arm(s): 'Tight' control.
B: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet
C: Arm Label: strict control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Arm Label: moderate control; Type: ACTIVE_COMPARATOR; Interventions: Other: target blood pressure | Intervention Type: OTHER; Name: target blood pressure; Assigned to Arm(s): moderate control, strict control
D: Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cluster Randomized Trial of Community Case Management of the Severe Pneumonia With Oral Amoxicillin in Children 2-59 Months of Age in Hala and Matiari District, Pakistan
Brief Summary: Two-arm cluster randomized controlled trial located in Hala district, Pakistan to determine the impact of using Lady Health Workers (LHW) of National Program for Family Planning and Primary Health Care to diagnose and manage severe pneumonia with oral amoxicillin on treatment failure rates at day 6 among 2-59 month old children. LHWs in the control arm receive a refresher in standard pneumonia case management. LHWs in the intervention arm receive standard training that is enhanced to include training in the recognition of severe pneumonia and its home management with oral amoxicillin. Clusters are by Union Council (UC), administrator units consisting of 7 to 25 LHWs; each UC is randomized to either enhanced pneumonia case management with oral amoxicillin therapy (intervention) for severe pneumonia or standard case management and referral to the nearest health facility for treatment (control). Process indicators reflecting the LHW's ability to assess, classify and treat pneumonia in the intervention group and cost-effectiveness data is also being collected.

Primary Hypothesis:

Enhanced pneumonia case management and oral amoxicillin therapy for severe pneumonia delivered by LHWs in the community will result in a reduction in treatment failure among children 2 - 59 months of age with severe pneumonia who are treated by the LHW compared with those referred for care by the LHW.

Secondary Hypotheses:

1. The proportion of treatment failure, \[persistence of lower chest indrawing (LCI) or need for second line treatment between day 3 and day 14\], will be less in the intervention arm compared with the control arm.
2. LHWs can adequately assess, classify, and treat severe pneumonia in 2 - 59 month old children, and adequately recognize and refer children who present with danger signs during initial antimicrobial therapy.


Options:
A: Arm Label: amoxicillin/clavulanic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxycillin/clavulanic acid | Arm Label: ceftriaxone/oxacillin; Type: ACTIVE_COMPARATOR; Interventions: Drug: ceftriaxone/oxacillin | Intervention Type: DRUG; Name: Amoxycillin/clavulanic acid; Assigned to Arm(s): amoxicillin/clavulanic acid | Intervention Type: DRUG; Name: ceftriaxone/oxacillin; Assigned to Arm(s): ceftriaxone/oxacillin
B: Intervention Type: DRUG; Name: Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: OTHER; Interventions: Drug: Amoxicillin | Arm Label: Control; Type: OTHER; Interventions: Other: Referral to Health facility | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Referral to Health facility; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Intestinal Helminths on Gut Microflora
Brief Summary: Albendazole is a main anti-helminth, however there is a lack of data regarding its efficacy in the school children population. The aim of this study is to evaluate the efficacy of the albendazole one versus two and three doses, in school children infected with intestinal helminth.


Options:
A: Arm Label: Subjects; Type: EXPERIMENTAL; Interventions: Drug: Albendazole Pill 400mg (GSK) | Intervention Type: DRUG; Name: Albendazole Pill 400mg (GSK); Assigned to Arm(s): Subjects
B: Intervention Type: DRUG; Name: Anti-helminthic; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: meglumine antimony; Assigned to Arm(s): N/A
C: Arm Label: Albendazole; Type: EXPERIMENTAL; Interventions: Drug: Albendazole | Intervention Type: DRUG; Name: Albendazole; Assigned to Arm(s): Albendazole
D: Arm Label: 1 dose, Albendazole , tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: albendazole | Arm Label: 2 doses, albendazole, tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: albendazole | Arm Label: 3 doses albendazole, 400mg, tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: albendazole | Intervention Type: DRUG; Name: albendazole; Assigned to Arm(s): 3 doses albendazole, 400mg, tablet | Intervention Type: DRUG; Name: albendazole; Assigned to Arm(s): 1 dose, Albendazole , tablet | Intervention Type: DRUG; Name: albendazole; Assigned to Arm(s): 2 doses, albendazole, tablet

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physician Dress Code And Microbial Colonization Of The White Coat: Does Physician Dress Code Alter Bacterial Colonization Rate On The Clothing Of Physicians?
Brief Summary: Governmental agencies in the United Kingdom and Scotland have recently instituted guidelines banning physicians' white coats and wearing of long-sleeved garments to decrease hospital transmission of bacteria. The purpose of this study is to compare the bacterial contamination of physicians' white coats with that of newly laundered, standardized short-sleeved uniforms after an eight-hour workday and to determine the rate at which bacterial contamination of the uniform ensues. Our hypothesis was that the physician white coat would have more bacterial contamination at the end of the work day.


Options:
A: Intervention Type: PROCEDURE; Name: Bathing with Chlorhexidine Impregnated Washcloths; Assigned to Arm(s): N/A
B: Arm Label: Beta-blocker adherence after an AMI; Type: EXPERIMENTAL; Interventions: Behavioral: Beta-blocker adherence after an AMI | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Beta-blocker adherence after an AMI; Assigned to Arm(s): Beta-blocker adherence after an AMI
C: Intervention Type: PROCEDURE; Name: Intensive Control Strategy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Standard Control Strategy; Assigned to Arm(s): N/A
D: Arm Label: White coat group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Uniform group; Type: EXPERIMENTAL; Interventions: Other: Physician uniform | Intervention Type: OTHER; Name: Physician uniform; Assigned to Arm(s): Uniform group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Brief Summary: This study will evaluate the efficacy of paliperidone palmitate compared with placebo in the delay of relapse of the symptoms of schizoaffective disorder. This study will also assess the safety and tolerability of paliperidone palmitate in patients with schizoaffective disorder.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: paliperidone palmitate | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): 001
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Paliperidone Palmitate | Arm Label: 002; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Paliperidone Palmitate; Assigned to Arm(s): 001
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Brexpiprazole (OPC-34712); Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole | Intervention Type: DRUG; Name: Brexpiprazole; Assigned to Arm(s): Brexpiprazole (OPC-34712) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Iloperidone; Type: EXPERIMENTAL; Interventions: Drug: Iloperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Iloperidone; Assigned to Arm(s): Iloperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating the Effectiveness of Dialectical Behaviour Skills Training for Suicidality in Borderline Personality Disorder
Brief Summary: The aim of this study is to evaluate the effectiveness of a 20-week Dialectical Behaviour Therapy (DBT) skills training group for the treatment of chronic suicidal and non-suicidal self-injurious (NSSI) behaviours in individuals diagnosed with borderline personality disorder (BPD). Previous research has established the effectiveness of a one year comprehensive, combined individual and group DBT treatment. However, in practice, DBT is often offered in a skills only group format. This study will consist of a randomized, controlled trial designed to evaluate the effectiveness of DBT compared to a wait list control. 84 participants will be randomized to the 20-week DBT group or the wait-list and the following outcomes will be assessed:

1. frequency of suicidal and NSSI behaviours
2. symptom distress
3. impulsivity
4. treatment retention
5. skill acquisition and
6. social functioning

Assessments will occur at pre-treatment, 10 weeks, 20 weeks and 3 months post treatment. The following main hypotheses will be examined: (1) Patients in the DBT skills group condition will have superior outcomes to patients on the treatment as usual wait list control in areas targeted by the treatment: frequency of suicidal and NSSI behaviours, emergency room visits, psychiatric hospital admissions, impulsivity, and knowledge and use of behavioral skills, general symptoms. The group receiving DBT will have superior outcomes at post treatment and these outcomes will be maintained during the three month post-treatment follow-up.


Options:
A: Arm Label: Brief Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Brief Intervention for Suicidality | Arm Label: care as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief Intervention for Suicidality; Assigned to Arm(s): Brief Intervention
B: Arm Label: Control (volitional help sheet); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Volitional help sheet | Arm Label: Intervention (volitional help sheet); Type: EXPERIMENTAL; Interventions: Behavioral: Volitional help sheet | Intervention Type: BEHAVIORAL; Name: Volitional help sheet; Assigned to Arm(s): Control (volitional help sheet) | Intervention Type: BEHAVIORAL; Name: Volitional help sheet; Assigned to Arm(s): Intervention (volitional help sheet)
C: Arm Label: 20 weeks skills group; Type: EXPERIMENTAL; Interventions: Behavioral: Skills Training | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Skills Training; Assigned to Arm(s): 20 weeks skills group
D: Arm Label: Cognitive Analytic Informed Brief Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive analytic informed brief therapy | Arm Label: Treatment As Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive analytic informed brief therapy; Assigned to Arm(s): Cognitive Analytic Informed Brief Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
Brief Summary: The primary purpose is to assess the efficacy and safety of eculizumab in pediatric patients with aHUS to control TMA as characterized by thrombocytopenia, hemolysis and renal impairment.


Options:
A: Arm Label: Ravulizumab; Type: EXPERIMENTAL; Interventions: Biological: Ravulizumab | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ravulizumab, Biological: Eculizumab | Intervention Type: BIOLOGICAL; Name: Ravulizumab; Assigned to Arm(s): Eculizumab, Ravulizumab | Intervention Type: BIOLOGICAL; Name: Eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: OMS721; Type: EXPERIMENTAL; Interventions: Biological: OMS721 | Intervention Type: BIOLOGICAL; Name: OMS721; Assigned to Arm(s): OMS721
C: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
D: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Observer-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of Three Formulations of the Novartis Vaccines Institute for Global Health (NVGH) Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age
Brief Summary: This trial is aimed to evaluate the safety and immunogenicity profiles of three formulations of Vi-CRM197 conjugate vaccine against S. Typhi in healthy human adults in comparison with the currently licensed Vi polysaccharide vaccine


Options:
A: Arm Label: NVGH Vi-CRM197 conjugate vaccine 12.5 mcg; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 12.5 mcg | Arm Label: NVGH Vi-CRM197 conjugate vaccine 5 mcg; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 5.0 mcg | Arm Label: NVGH Vi-CRM197 conjugate vaccine 1.25 mcg; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 1.25 mcg | Arm Label: Typherix; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vi-polysaccharide vaccine | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197 12.5 mcg; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine 12.5 mcg | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197 5.0 mcg; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine 5 mcg | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197 1.25 mcg; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine 1.25 mcg | Intervention Type: BIOLOGICAL; Name: Vi-polysaccharide vaccine; Assigned to Arm(s): Typherix
B: Arm Label: NVGH Vi-CRM197 conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NVGH Vi-CRM197 | Arm Label: Vi-polysaccharide vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Typherix | Intervention Type: BIOLOGICAL; Name: Typherix; Assigned to Arm(s): Vi-polysaccharide vaccine | Intervention Type: BIOLOGICAL; Name: NVGH Vi-CRM197; Assigned to Arm(s): NVGH Vi-CRM197 conjugate vaccine
C: Arm Label: M01ZH09 vaccine; Type: EXPERIMENTAL; Interventions: Biological: M10ZH09 vaccine | Arm Label: Vaccine placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vaccine placebo (excipients only) | Arm Label: Ty21a vaccine; Type: OTHER; Interventions: Biological: Ty21a | Intervention Type: BIOLOGICAL; Name: Vaccine placebo (excipients only); Assigned to Arm(s): Vaccine placebo | Intervention Type: BIOLOGICAL; Name: Ty21a; Assigned to Arm(s): Ty21a vaccine | Intervention Type: BIOLOGICAL; Name: M10ZH09 vaccine; Assigned to Arm(s): M01ZH09 vaccine
D: Arm Label: Vi-TCV; Type: EXPERIMENTAL; Interventions: Biological: Vi-TCV | Arm Label: Vi-PS Vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Vi-PS Vaccine | Arm Label: Control (Men ACWY); Type: OTHER; Interventions: Biological: Control (Men ACWY) | Intervention Type: BIOLOGICAL; Name: Vi-TCV; Assigned to Arm(s): Vi-TCV | Intervention Type: BIOLOGICAL; Name: Vi-PS Vaccine; Assigned to Arm(s): Vi-PS Vaccine | Intervention Type: BIOLOGICAL; Name: Control (Men ACWY); Assigned to Arm(s): Control (Men ACWY)

Answer: A